In this blog post, NCCIH Director of External Research Dr. Emmeline Edwards discusses NIH/NCCIH funding opportunities in music and art therapies.
In this blog post, NCCIH Director Dr. Josephine Briggs discusses new pathways for clinical trial funding.
Genetic Edge Compounds voluntarily recalls all lot codes distributed between February 2, 2015-May 2, 2017 of GEC Laxoplex dietary supplement capsules.
In this blog post, Dr. Wen Chen discusses two Program Announcements (PARs) that direct research attention toward investigating the mechanisms by which mind and body interventions might work, as well as strategies to optimize these interventions.
FTC says not to trust dietary supplements promoted for opiate withdrawal.
Find out more about a new series of funding opportunity announcements for investigator-initiated clinical trials, and register for this May 9 webinar: New NCCIH Funding Opportunities for Natural Products Clinical Trials.
FDA advises consumers not to purchase or use Monkey Business, a product promoted for sexual enhancement.
Eye conditions that can lead to permanent visual impairment or blindness—including age-related macular degeneration (AMD), cataracts, diabetic retinopathy, and glaucoma—are serious public health problems.
Four important things to know about dietary supplements and eye diseases.
In this blog post, Dr. Lanay Mudd discusses the purpose of pilot studies and points to NCCIH’s new “Framework for Developing and Testing Mind and Body Interventions.”
One thing that is important to know about autism up front: There is no cure for autism. So, products or treatments claiming to “cure” autism do not work as claimed. The same is true of many products claiming to “treat” autism or autism-related symptoms. Some may carry significant health risks.
The Food and Drug Administration (FDA) plays an important role in warning these companies against making improper claims about their products’ intended use as a treatment or cure for autism or autism-related symptoms.
FDA issued warning letters to 14 U.S.-based companies illegally selling products that fraudulently claim to prevent, diagnose, treat or cure cancer.
Organic Herbal Supply, Inc. recalls all lots of Uproar, Cummor, Zrect, Monkey Business, Xrect, Rectalis, Tornado, Zdaily, BigNHard, Enhancerol Natural Male Enhancement capsules.
At NCCIH, we are working hard to let the research community know about our new approach to funding research with human subjects that focuses on the clinical effects of complementary health approaches.
FDA alerts consumers to voluntary recall of Hyland’s Baby Teething Tablets and Hyland’s Baby Nighttime Teething Tablets for belladonna.
In this blog post, NCCIH Deputy Director Dr. David Shurtleff commends Dr. Martin Goldrosen, who is retiring, and Dr. Partap Khalsa, who has been appointed Director of the NCCIH Division of Extramural Activities.
NCCIH to host informational webinars in April and May, 2017, on clinical trial applications via new funding opportunities.
A new study, supported in part by NCCIH, counters some long-held beliefs on sleep, dreaming, and other consciousness states.
NCCIH-supported researchers created a functional MRI-based (fMRI) model that provides new ways of understanding and evaluating the neurobiological components of pain.
In this blog post, Dr. Emmeline Edwards announces new NCCIH roles for Drs. Craig Hopp and Wen Chen.